449 related articles for article (PubMed ID: 32393323)
1. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
2. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
Yin L; Liu KC; Lv WF; Xu SB; Lu D; Zhou CZ; Cheng DL; Gao ZG; Shi CS; Su MX
Drug Des Devel Ther; 2022; 16():3421-3429. PubMed ID: 36203820
[TBL] [Abstract][Full Text] [Related]
3. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
5. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
[TBL] [Abstract][Full Text] [Related]
6. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
Qu W; Wang F; Qin S; Sun Y; Huang C
Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
Song G; Zhang FF; Cheng HD
Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
[TBL] [Abstract][Full Text] [Related]
9. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
10. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
[TBL] [Abstract][Full Text] [Related]
11. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
[TBL] [Abstract][Full Text] [Related]
12. Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report.
Liu J; Cao G; Zhang G; Liu S; Shi D
J Gastrointest Oncol; 2023 Jun; 14(3):1643-1649. PubMed ID: 37435210
[TBL] [Abstract][Full Text] [Related]
13. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
Hua Y; Huang X; Li C; Gao N
Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
[TBL] [Abstract][Full Text] [Related]
14. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.
Ma R; Wang JL; Wang YY
Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
16. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
[No Abstract] [Full Text] [Related]
17. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
[TBL] [Abstract][Full Text] [Related]
18. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
19. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.
Wang C; Lei K; Jia Y; Jiang Z; Wang S
Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Ni J; Si X; Wang H; Zhang X; Zhang L
Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]